UEMS Medical Specialty

Neurology & CNS

Research covering the central and peripheral nervous system, blood–brain barrier (BBB) permeability, neuroinflammation, neurodegenerative diseases, and brain-targeted nutraceutical delivery systems.

24

dossiers

Catecholamine Homeostasis & Executive Function

ADHD and Autism Spectrum Disorder: Overlap, Distinctions, and Shared Genetic Influences

Developing targeted therapies for neurodevelopmental disorders like ADHD and ASD is challenging due to their significant clinical and genetic overlap, often leading to more severe comorbid presentations that complicate differential diagnosis and treatment efficacy.

Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder Comorbidity Genetic Predisposition to Disease

Catecholamine Homeostasis & Executive Function

Clinical Advancements in Brain-Computer Interfaces: Speech, Motor, and Sensory Neuroprosthetics

Ensuring the long-term biocompatibility and stable performance of high-density neural interfaces within the dynamic CNS presents significant material science and biointegration challenges for sustained therapeutic device efficacy.

Brain-Computer Interfaces Neuroprostheses Spinal Cord Injuries Amyotrophic Lateral Sclerosis

Catecholamine Homeostasis & Executive Function

Borderline Personality Disorder: Diagnostic Validity, Overlap, and Nosological Models

The intricate diagnostic landscape of Borderline Personality Disorder (BPD), marked by significant symptom overlap and debate on its construct validity, poses a critical challenge for developing precisely targeted pharmaceutical or nutraceutical interventions.

Borderline Personality Disorder Diagnosis, Differential Validity of Tests Comorbidity

Catecholamine Homeostasis & Executive Function

Catecholamine Homeostasis and Executive Function: Optimizing Nutritional Product Formulations

Achieving stable and predictable cognitive benefits from dopaminergic nutritional products is challenging due to exposure variability ('spike-and-crash' kinetics) and the complex interplay of precursors, cofactors, and enzymatic bottlenecks in catecholamine biosynthesis.

Catecholamines Executive Function Dopamine Tyrosine Hydroxylase

Post-GLP-1 Metabolic Optimization

Drug-Induced Nutrient Depletion (DIND): Molecular Mechanisms of Iatrogenic Deficiencies in Chronic Pharmacotherapy

Mitigating drug-induced nutrient depletion requires advanced CDMO solutions to formulate targeted nutritional support that is compatible with existing chronic pharmacotherapy and addresses diverse mechanistic pathways of depletion.

Drug-Related Side Effects and Adverse Reactions Nutritional Deficiency Hydroxymethylglutaryl-CoA Reductase Inhibitors Ubiquinone

Precision Microbiome & Gut-Brain Axis

Hidden Pharmacodynamics of Pharmaceutical Formulations: Excipient, Impurity, and Oxidation Index Impact on Clinical Safety

Pharmaceutical and nutraceutical formulations often overlook the direct pharmacodynamic effects of excipients and the toxicity of oxidation byproducts, risking unforeseen clinical safety issues that extend beyond the API's profile.

Excipients Drug Safety Gut Microbiome Intestinal Mucosa

Precision Microbiome & Gut-Brain Axis

Gut-Brain Axis and Mental Illness: Microbiota, Mechanisms, and Testable Hypotheses

Translating complex gut-brain axis insights into effective, targeted formulations for psychiatric conditions requires addressing variable microbiome signatures, diverse mechanistic pathways, and inconsistent clinical trial outcomes.

Microbiota-Gut-Brain Axis Mental Disorders Depressive Disorder, Major Anxiety Disorders

Cellular Longevity & Senolytics

Immunometabolism, Active Resolution of Inflammation, and Specialized Pro-resolving Mediators (SPMs) from EPA/DHA

Current anti-inflammatory strategies often inhibit active resolution pathways, leading to chronic inflammation. Developing stable, bioavailable specialized pro-resolving mediators (SPMs) or modulators that enhance endogenous SPM biosynthesis without compromising resolution is a significant challenge.

Specialized Pro-Resolving Mediators Resolvins Protectins Lipoxins

Catecholamine Homeostasis & Executive Function

Kava (Piper methysticum) in Psychiatry: Clinical Effects, Mechanisms, and Safety Signals with Emphasis on Anxiety Disorders

Developing safe and effective Kava-derived anxiolytics is challenging due to inherent hepatotoxicity concerns and potential herb-drug interactions, necessitating novel formulation strategies to mitigate adverse events while preserving therapeutic efficacy.

Piper methysticum Anxiety Disorders Anxiolytic Agents Kavalactones

Catecholamine Homeostasis & Executive Function

Narcissistic Parenting and ADHD: Indirect Pathways and Diagnostic Implications

Precisely differentiating ADHD from trauma-related phenocopies in children of narcissistic parents presents a significant diagnostic hurdle, complicating targeted therapeutic development.

Attention Deficit Disorder with Hyperactivity Parents Narcissism Child Abuse

Precision Microbiome & Gut-Brain Axis

The Neuroimmune Continuum: Mechanisms, Paradigm Shifts, and Translational Frontiers in Psychoneuroimmunology

Translating complex psychoneuroimmunological mechanisms, including BBB permeability, specific cytokine pathways, and targeted microglial modulation, into stable and bioavailable therapeutic formulations presents a significant CDMO hurdle.

Psychoneuroimmunology Neuroinflammation Stress, Psychological Microbiota-Gut-Brain Axis

Post-GLP-1 Metabolic Optimization

Nutraceutical Toxicology and Herb-Drug Interactions (HDI/NDI): A Clinical Review of Six Critical Pharmacological Mechanisms

Developing safe and effective drug formulations requires comprehensive consideration of potential, often undisclosed, herb-drug interactions that can compromise efficacy or lead to life-threatening toxicities, especially with narrow therapeutic index compounds.

Drug Interactions Nutraceuticals Herb-Drug Interactions Cytochrome P-450 Enzyme System

Precision Microbiome & Gut-Brain Axis

Pharmacomicrobiomics: Gut Microbiota Modulation of Drug Efficacy and Nutraceutical Biotransformation

Integrating the profound and variable metabolic capacity of the gut microbiome into pharmaceutical development to ensure consistent drug efficacy and bioavailability across diverse patient populations is a significant hurdle.

Pharmacomicrobiomics Gut Microbiota Drug Metabolism Xenobiotics

Catecholamine Homeostasis & Executive Function

Posttraumatic Stress Disorder, Complex PTSD, and Attention-Deficit/Hyperactivity Disorder: Comorbidity and Shared Mechanisms

The high comorbidity and overlapping symptomatology of PTSD, CPTSD, and ADHD present a key challenge. Developing precise therapies requires unraveling their complex, shared neurobiological mechanisms.

Post-Traumatic Stress Disorder Attention Deficit Disorder with Hyperactivity Comorbidity Trauma and Stressor Related Disorders

Cerebral Bioenergetics & Neuro-Metabolic Rescue

Quantum Theories of Consciousness in Psychiatry: The Orchestrated Objective Reduction (Orch-OR) Hypothesis

Developing therapeutic interventions that modulate consciousness or psychiatric pathology requires targeting quantum-level phenomena within neuronal microtubules, posing a significant challenge for conventional drug design and delivery given the elusive nature of these mechanisms.

Consciousness Mental Disorders Quantum Theory Microtubules

Cerebral Bioenergetics & Neuro-Metabolic Rescue

Quantum Physics and Medicine: A Review of Common Aspects

Integrating quantum phenomena, essential for advanced diagnostics and computation, into stable and functional biomedical devices for precise clinical application amidst complex biological environments presents a significant CDMO hurdle.

Quantum Theory Physics Medicine Diagnostic Imaging

Catecholamine Homeostasis & Executive Function

Quantum Physics and Psychiatry: Methodological and Metaphorical Parallels

Integrating the inherent subjectivity and observer-dependent dynamics described by quantum-psychiatry parallels into objective, reproducible clinical trial designs and drug development pathways for mental health remains a significant challenge for pharmaceutical R&D.

Psychiatry Psychotherapy Quantum Theory Uncertainty Principle

Cellular Longevity & Senolytics

Cellular Senescence, SASP, and Senolytic Targeting of Age-Related Pathologies

Delivering senolytics effectively to specific senescent cell populations and overcoming their multi-pathway pro-survival redundancy (SCAPs) without off-target effects remains a significant challenge for therapeutic development.

Cellular Senescence Senescence-Associated Secretory Phenotype Senolytics Aging

Catecholamine Homeostasis & Executive Function

Clinical Nutrigenomics: One-Carbon Metabolism, MTHFR/COMT Polymorphisms, and Unmetabolized Folic Acid Toxicity

Developing stable, bioavailable dosage forms of 5-methyltetrahydrofolate (5-MTHF) that effectively bypass common one-carbon metabolism genetic polymorphisms (e.g., MTHFR, COMT) is critical to prevent unmetabolized folic acid (UMFA) toxicity and ensure optimal folate status. This requires precise formulation to overcome stability issues inherent to reduced folates while ensuring clinical efficacy across genetically diverse populations.

Folic Acid MTHFR Protein Catechol O-Methyltransferase 5-Methyltetrahydrofolate

Cerebral Bioenergetics & Neuro-Metabolic Rescue

Ketogenic Diet-Specified Interventions in Neurodegenerative Disease Mechanisms

Developing a formulation that achieves consistent and measurable ketosis while optimizing bioavailability and tolerability in neurodegenerative conditions is a key challenge.

Alzheimer Disease Parkinson Disease Neurodegenerative Diseases Neuroinflammation

Advanced BBB Permeability Solutions

Lipidic Nanoformulations for BBB Transport of Lipophilic Phytochemicals: Current Evidence and Challenges

Lipophilic phytochemicals exhibit poor systemic and brain bioavailability due to rapid metabolism, low solubility, and active efflux at the blood-brain barrier, impeding clinical translation.

Blood-Brain Barrier Catecholamines Nanoparticles Liposomes

Precision Microbiome & Gut-Brain Axis

Nutrition and Psychiatric Disorders: A Comprehensive Narrative Review of the Evidence Through 2026

Optimal dietary interventions for psychiatric disorders remain poorly standardized and show high variability in effectiveness.

Attention Deficit Disorder with Hyperactivity Anxiety Depression Gastrointestinal Microbiome

Precision Microbiome & Gut-Brain Axis

Enteric Delivery of Butyrate: Overcoming Gastrointestinal Barriers for Vagal Activation

Free butyrate salts dissolve prematurely in the upper gastrointestinal tract, limiting their availability for distal gut signaling. Additionally, their pungent odor and taste present significant challenges for patient adherence in chronic applications.

Aging Serotonin Gastrointestinal Microbiome Fatty Acids, Volatile

Precision Microbiome & Gut-Brain Axis

Gut-Brain Axis in ADHD: Microbiota-Mediated Dopaminergic Pathway Modulation

Developing scientifically validated microbiome-targeted interventions for ADHD involves addressing the challenges of heterogeneity in clinical outcomes and identifying precise microbial mechanisms. Formulating stable, effective probiotics or synbiotics with demonstrated clinical benefits remains a major hurdle.

Neuroinflammation Attention Deficit Disorder with Hyperactivity Dopamine Serotonin

Custom Formulation Available

Need a Dossier Built Around Your Molecule?

Our R&D team will conduct a Paid Discovery Audit and build a proprietary clinical dossier for your specific active ingredient or therapeutic target. Full IP transfer included.